From the data available the vaccines look to be efficacious and protection lasts at least two years (this is the extent of available duration data at present not a hard ceiling on it).
The companies expect the vaccines will be available before next RSV season.
The CDC director Rochelle Walenksy will do the final approval before it can be available. This will probably be one of her final acts as director before Mandy Cohen takes over.
ACIP had some reservations based on limited information. Final prices aren't set for the vaccines, only estimates of price ranges. So ACIP was limited in its ability to project cost effectiveness. But as we've seen in the past with the HPV vaccine and others, this will likely evolve over time with more data.